Further, lymphangiogenesis and angiogenesis are promoted by M2-like (high ratio of CD163+/CD68+) TAMs, whereby a high expression of VEGF-C and VEGF-A by M2-like macrophages was reported in patients with non-small-cell lung cancer (NSCLC) [99]. Here, CD163 is linked to non-small cell lung carcinoma.